a phase 0 multicenter study of the pharmacodynamic effects of intratumoral microdose administration of pba-0111 in patients with solid tumors

Conditions: Head and Neck Squamous Cell Carcinoma; Soft Tissue Sarcoma Adult; Triple Negative Breast Cancer

Summary: this is a multi-center, single arm, open-label, localized pharmacodynamic biomarker phase 0 trial designed to study the biological effects within the tumor microenvironment of pba-0111 when administered intratumorally in microdose quantities via the civo device.

civo is a research tool composed of a hand-held single-use sterile injector coupled with fluorescent tracking microspheres called civo glo that mark the sites of drug microdose injection, enabling rapid assessment of multiple oncology drugs or drug combinations simultaneously within a patient's tumor. in this phase 0 intratumoral microdosing study in human patients with localized or metastatic primary hnscc, sts, or tnbc tumors (who will be undergoing previously planned tumor and regional nodes dissection), we will evaluate pba-0111's ability to trigger a variety of immune-mediated effector functions that kill tumor cells, within the local tumor microenvironment. the civo device penetrates solid tumors and delivers subtherapeutic microdoses of up to eight anti-cancer agents or combinations of anti-cancer agents co-injected with civo glo into discrete regions of the tumor. at the time of the planned surgical intervention (one to two days after the civo microdose injection), the injected tumor tissue is then excised, and tumor responses are assessed via histological staining of tumor cross-sections sampled perpendicular to each injection column. co-injection with civo glo enables identification of each injection site during resection as well as in tissues stained for analysis. because the platform delivers microdose amounts of each test agent or combination directly into the patient's tumor tissue, hypotheses can be tested earlier in the drug development process, consistent with the goals of the 2006 fda exploratory ind guidance for industry.

Eligibility criteria:
inclusion criteria: 1. ability and willingness to comply with the study's visit and assessment schedule. 2. male or female ≥ 18 years of age at visit 1 (screening). 3. pathologic diagnosis of hnscc, sts (see restrictions in note below), or tnbc (see restrictions in note below; tnbc defined as estrogen receptor negative \[\<1% positive tumor cells\], progesterone receptor negative \[\<1% positive tumor cells\], and human epidermal growth factor receptor 2 negative \[0 to 1+\]) with a tumor planned for surgical resection. note: for sts, only the following subtypes are eligible: undifferentiated pleomorphic sarcoma, alveolar soft part sarcoma, synovial sarcoma, cutaneous angiosarcoma, or myxofibrosarcoma. note: for tnbc, if prior neoadjuvant therapy, evidence of progressive disease, at the discretion of the investigator. 4. ability and willingness to provide written informed consent. voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care. 5. as assessed or confirmed by the surgeon, at least one lesion (primary tumor, recurrent tumor, metastatic tumor, or metastatic lymph node) that is surface accessible for civo injection that contains viable minimum tumor tissue volume and characteristics (e.g., based on clinical evaluation, available pre-operative imaging, pre-injection ultrasound imaging, or pathology reports indicating lesion with appropriate viable tumor volume without excessive cysts or necrosis) and for which there is a planned surgical intervention. the patient's presentation, surgical and pathology plan may determine whether a lesion is eligible with respect to a given civo mid needle configuration. 6. eastern cooperative oncology group (ecog) performance status of 0-2. 7. female patients who: • are postmenopausal for at least one year before the screening visit, or • are surgically sterile, or • are of childbearing potential who agree to practice a highly effective method of contraception from the time of signing the icf up to 3 months following the end of study participation or agree to completely abstain from heterosexual intercourse. • agree to refrain from donating ova during study participation. male patients, even if surgically sterile (i.e., status post-vasectomy), who: • agree to practice effective barrier contraception from the time of signing the icf up to 3 months following the end of study participation or agree to completely abstain from heterosexual intercourse. • agree to refrain from donating sperm during study participation. exclusion criteria: 1. tumors near or involving critical structures for which, in the opinion of the treating clinician, injection would pose undue risk to the patient. 2. female patients who are: • both lactating and breastfeeding, or • have a positive β-subunit human chorionic gonadotropin (β-hcg) pregnancy test at screening verified by the investigator. 3. any uncontrolled intercurrent illness, condition, serious medical or psychiatric illness, or circumstance that, in the opinion of the investigator, could interfere with adherence to the study's procedures or requirements, or otherwise compromise the study's objectives. 4. hnscc known to be of cutaneous origin. 5. patients with uncontrolled autoimmune diseases (see appendix 1 for examples) requiring systemic treatment 6. patients with known hiv/aids. 7. patients with known uncontrolled active hepatitis b (defined as hepatitis b surface antigen \[hbsag\] positive or detectable hepatitis b virus \[hbv\] dna) or hepatitis c (defined as anti-hepatitis c virus antibody \[anti-hcv ab\] positive and detectable hepatitis c virus \[hcv\] rna) infection. note: hepatitis b and c screening tests are not required unless: • patient has a known history of hepatitis b/c infection • mandated by local health authority 8. use of any of the following ≤ 3 weeks prior to civo injection: a. systemic anti-cancer therapy (e.g., cytotoxic chemotherapy, targeted agents, or checkpoint inhibitor immunotherapy, etc.), b. immunosuppressive drugs (e.g., calcineurin inhibitors) c. biological response modifiers for autoimmune disease d. systemic glucocorticoids: oral or parenteral corticosteroids at a dose ≥ 20 mg/day prednisone, or equivalent note: physiologic replacement dosing of steroids (≤ 3 mg/m2/d prednisone or equivalent), low-dose corticosteroids for dye allergies prior to staging scans or use in anti-emetic prophylaxis for patients undergoing chemotherapy, or topical steroids, are allowed e. hematopoietic growth factors f. chemotherapy g. local radiotherapy of the target lesion planned for civo injection and surgical resection 9. patients who have received a live or live attenuated vaccine within 4 weeks of the baseline/screening visit. 10. patients who have had allogenic tissue/solid organ transplant 11. patients with an active infection requiring systemic therapy. 12. patients for whom participation on this study results in a delay of planned surgical intervention.

Keywords: pure biologics pba-0111 tnbc sts hnscc tumor microenvironment in vivo drug sensitivity in vivo oncology microdosing microinjection intratumoral injection precision oncology